Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
MOMA Therapeutics
MOMA Therapeutics
AstraZeneca
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Pfizer
Memorial Sloan Kettering Cancer Center
Amgen
National Institutes of Health Clinical Center (CC)
Rutgers, The State University of New Jersey
International Agency for Research on Cancer
City of Hope Medical Center
GlaxoSmithKline
Atavistik Bio, Inc
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Hoffmann-La Roche
Duke University
AstraZeneca
Poseida Therapeutics, Inc.
AstraZeneca
University of Kansas Medical Center
University of Washington
Memorial Sloan Kettering Cancer Center
M.D. Anderson Cancer Center
Brigham and Women's Hospital
Seagen Inc.
Varian, a Siemens Healthineers Company
Implenomics
Assistance Publique - Hôpitaux de Paris
BicycleTx Limited
SystImmune Inc.
Vanderbilt-Ingram Cancer Center
Masonic Cancer Center, University of Minnesota
Sensei Biotherapeutics, Inc.
Jonsson Comprehensive Cancer Center
Memorial Sloan Kettering Cancer Center
University of Alabama at Birmingham
University of Chicago
Eli Lilly and Company
OncoC4, Inc.
Klus Pharma Inc.
Tempus AI
N.N. Petrov National Medical Research Center of Oncology
Cybrexa Therapeutics
Carisma Therapeutics Inc
UNICANCER
The University of Texas Health Science Center, Houston
University of Toronto
Shanghai PerHum Therapeutics Co., Ltd.
NGM Biopharmaceuticals, Inc